AU8182298A - Recombinant erythropoietin / immunoglobulin fusion proteins - Google Patents
Recombinant erythropoietin / immunoglobulin fusion proteinsInfo
- Publication number
- AU8182298A AU8182298A AU81822/98A AU8182298A AU8182298A AU 8182298 A AU8182298 A AU 8182298A AU 81822/98 A AU81822/98 A AU 81822/98A AU 8182298 A AU8182298 A AU 8182298A AU 8182298 A AU8182298 A AU 8182298A
- Authority
- AU
- Australia
- Prior art keywords
- fusion proteins
- immunoglobulin fusion
- recombinant erythropoietin
- erythropoietin
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000003951 Erythropoietin Human genes 0.000 title 1
- 108090000394 Erythropoietin Proteins 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 229940105423 erythropoietin Drugs 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88982997A | 1997-07-10 | 1997-07-10 | |
| US08889829 | 1997-07-10 | ||
| PCT/US1998/013930 WO1999002709A1 (en) | 1997-07-10 | 1998-07-06 | Recombinant erythropoietin / immunoglobulin fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU8182298A true AU8182298A (en) | 1999-02-08 |
Family
ID=25395872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU81822/98A Abandoned AU8182298A (en) | 1997-07-10 | 1998-07-06 | Recombinant erythropoietin / immunoglobulin fusion proteins |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU8182298A (en) |
| WO (1) | WO1999002709A1 (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999029732A2 (en) | 1997-12-08 | 1999-06-17 | Lexigen Pharmaceuticals Corporation | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| IL145785A0 (en) * | 1999-05-07 | 2002-07-25 | Genentech Inc | Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same |
| US6831060B2 (en) | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| US6555343B1 (en) | 1999-05-07 | 2003-04-29 | Genentech Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| DE60040225D1 (en) * | 1999-07-13 | 2008-10-23 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2001010912A1 (en) | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| JP2003514552A (en) * | 1999-11-12 | 2003-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Erythropoietin morphology with improved properties |
| WO2001058957A2 (en) | 2000-02-11 | 2001-08-16 | Lexigen Pharmaceuticals Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
| US7517526B2 (en) | 2000-06-29 | 2009-04-14 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| EP1366067B1 (en) * | 2001-03-07 | 2012-09-26 | Merck Patent GmbH | Expression technology for proteins containing a hybrid isotype antibody moiety |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| US7265208B2 (en) | 2001-05-01 | 2007-09-04 | The Regents Of The University Of California | Fusion molecules and treatment of IgE-mediated allergic diseases |
| DE60239454D1 (en) | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE |
| KR100467750B1 (en) * | 2001-11-29 | 2005-01-24 | 씨제이 주식회사 | Fusion protein having the enhanced in vivo activity of erythropoietin |
| ATE542137T1 (en) | 2001-12-04 | 2012-02-15 | Merck Patent Gmbh | IMMUNOCYTOKINE WITH MODULATED SELECTIVITY |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| BRPI0317376B8 (en) | 2002-12-17 | 2021-05-25 | Merck Patent Gmbh | antibody-il2 fusion protein designated as hu14.18-il2, uses thereof, vector and pharmaceutical composition |
| JP2007531707A (en) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ， インコーポレイテッド | Modification of Fc fusion protein serum half-life by mutagenesis of heavy chain constant region positions 250, 314 and / or 428 of IG |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| RU2352583C2 (en) | 2003-11-13 | 2009-04-20 | Ханми Фарм. Инд. Ко., Лтд. | PHARMACEUTICAL COMPOSITION CONTAINING Fc-REGION OF IMMUNOGLOBULIN AS CARRIER |
| EP1699822B1 (en) | 2003-12-30 | 2008-04-23 | MERCK PATENT GmbH | Il-7 fusion proteins with antibody portions, their preparation and their use |
| PT1699821E (en) | 2003-12-31 | 2012-08-23 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| JP2007517506A (en) | 2004-01-05 | 2007-07-05 | イーエムディー・レキシゲン・リサーチ・センター・コーポレーション | Targeting compounds |
| RU2437893C2 (en) | 2004-12-09 | 2011-12-27 | Мерк Патент Гмбх | Il-7 versions with low immunising capacity |
| US7968316B2 (en) | 2005-08-16 | 2011-06-28 | Hanmi Holdings Co., Ltd. | Method for the mass production of immunoglobulin Fc region deleted initial methionine residues |
| US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| DK1961821T3 (en) * | 2007-02-22 | 2009-10-12 | Polymun Scient Immunbio Forsch | Erythropoietin Fusion Protein |
| TWI554520B (en) * | 2007-07-20 | 2016-10-21 | 諾華健控股公司 | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| CA2720628A1 (en) | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
| WO2010121766A1 (en) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE309376T1 (en) * | 1990-06-28 | 2005-11-15 | Hoechst Ag | FUSION PROTEINS WITH IMMUNGLOBULIN COMPONENTS, THEIR PRODUCTION AND USE |
| EP0667903A1 (en) * | 1992-07-28 | 1995-08-23 | New England Deaconess Hospital | Recombinant human erythropoietin with altered biological activity |
| US5580853A (en) * | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
-
1998
- 1998-07-06 AU AU81822/98A patent/AU8182298A/en not_active Abandoned
- 1998-07-06 WO PCT/US1998/013930 patent/WO1999002709A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999002709A1 (en) | 1999-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU8182298A (en) | Recombinant erythropoietin / immunoglobulin fusion proteins | |
| AU7274898A (en) | Recombinant antibody-enzyme fusion proteins | |
| AU3827695A (en) | Antigen-binding fusion proteins | |
| AU5065198A (en) | Fusion proteins having increased half-lives | |
| AU9482098A (en) | Fusion protein systems | |
| GB9718609D0 (en) | Fusion protein | |
| AU4382193A (en) | BPI-immunoglobulin fusion proteins | |
| AU3562299A (en) | Inhibin-hbc fusion protein | |
| AU6255096A (en) | Pegylated modified proteins | |
| AU4572899A (en) | Variant type ii tgf-beta receptor fusion proteins and methods | |
| AU2002300207A1 (en) | Recombinant Rhabdovirus containing a heterologous Fusion Protein | |
| AU1631000A (en) | Immunoglobulin superfamily proteins | |
| AU5553600A (en) | Fusion proteins incorporating lysozyme | |
| AU5681498A (en) | A ctla4-ig fusion protein having high titer | |
| AU6873596A (en) | Allergen-xcd32 fusion proteins | |
| AU9798398A (en) | Gfp-annexin fusion proteins | |
| AU7125498A (en) | Novel multidrug resistance-associated polypeptide | |
| AU5635896A (en) | Recombinant endotoxin-neutralizing proteins | |
| AU2497095A (en) | Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide | |
| AU9105698A (en) | Rab proteins | |
| AU1526897A (en) | Fusion proteins comprising cell cycle regulatory proteins | |
| AU6000698A (en) | Proteins | |
| AU8176798A (en) | Secreted proteins | |
| AU9109998A (en) | High affinity immunoglobulin e receptor-like protein | |
| AU4661697A (en) | Pfs28 fusion proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |